Is there a case for PSA screening, after all?
Recommendations against prostate cancer screening may need to be revised after a reanalysis of the evidence found prostate-specific antigen (PSA) testing significantly reduces mortality.
However, questions remain about how to implement screening so the benefits outweigh the potential harms of overdiagnosis and overtreatment.
Current RACGP guidelines recommend against PSA screening in primary care and this position is mirrored in the US.
However, the authors of the latest analysis note that the US recommendation relies heavily on results from the ERSPC (European Randomized Study of